Contact Us    |      Join    |

"The Voice of Oncology in Massachusetts"

FDA approved zanubrutinib (Brukinsa) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

January 20, 2023 2:46 PM | Katy Monaco (Administrator)

FDA) approved zanubrutinib (Brukinsa, BeiGene USA, Inc.) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read More. 

View full prescribing information for Brukinsa.


ADDRESS

860 Winter Street, Waltham, MA, 02451

CONTACT US

tel: 781.434.7329

msco@mms.org

Massachusetts Society of Clinical Oncologists ©2024

Powered by Wild Apricot Membership Software